A Phase 1/2, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
Latest Information Update: 04 Apr 2025
At a glance
- Drugs MRNA-1403 (Primary) ; MRNA-1405 (Primary)
- Indications Norovirus infections
- Focus Adverse reactions
- Sponsors Moderna Therapeutics
- 13 Sep 2024 Planned End Date changed from 14 Apr 2025 to 20 Nov 2025.
- 05 Jun 2024 Planned End Date changed from 7 May 2025 to 14 Apr 2025.
- 05 Jun 2024 Planned primary completion date changed from 7 May 2025 to 14 Apr 2025.